Biopharmaceutical Biz Closes $259M Upsized Funding Round

By Jade Martinez-Pogue · March 6, 2024, 3:31 PM EST

South San Francisco, California-based clinical-stage biopharmaceutical company Alumis Inc. on Wednesday announced that it closed its upsized Series C funding round after securing $259 million from venture capital investors....

To view the full article, register now.